| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M L Vance, J R Cragun, C Reimnitz, R J Chang, E Rashef, R E Blackwell, M M Miller, M E Molitc. CV 205-502 treatment of hyperprolactinemia. The Journal of clinical endocrinology and metabolism. vol 68. issue 2. 1989-03-27. PMID:2521863. |
cv 205-502, given once daily, appears to be a safe and effective alternative to other dopamine agonists in the treatment of hyperprolactinemia. |
1989-03-27 |
2023-08-11 |
Not clear |
| b' G M Prelevi\\xc4\\x87, M I W\\xc3\\xbcrzburger, L A Peri\\xc4\\x8. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome. Journal of endocrinological investigation. vol 11. issue 4. 1988-10-03. PMID:3137253.' |
a relative dopamine deficiency might cause hypersecretion of prl and lh in patients with pcos and hyperprolactinemia. |
1988-10-03 |
2023-08-11 |
human |
| W F Silverman, R J Wals. Prolactin causes increased turnover of dopamine in 10-day-old rat median eminence. The Anatomical record. vol 217. issue 1. 1988-09-13. PMID:3454564. |
chronic but not acute hyperprolactinemia resulted in increased dopamine release relative to vehicle-treated controls, as shown by diminished fluorescence intensity in the median eminence. |
1988-09-13 |
2023-08-11 |
rat |
| L E Hanssen, J Brownell, J Halse, J Jervell, K T Stokke, S Reinlie, S Stray-Pederse. CQP 201-403, a new dopamine agonist in the treatment of hyperprolactinemia. Acta endocrinologica. vol 117. issue 4. 1988-07-29. PMID:3291529. |
cqp 201-403, a new dopamine agonist in the treatment of hyperprolactinemia. |
1988-07-29 |
2023-08-11 |
Not clear |
| C Giammartino, F Ambrosi, G Pelicci, M C Pagliacci, L Fedeli, I Nicolett. Catecholamines and pituitary function. VII: Effects of acute and chronic dopamine-receptor blockade on pituitary response to TRH-GNRH in normal women and in patients with hyperprolactinemic amenorrhea. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 20. issue 1. 1988-07-06. PMID:3131222. |
to investigate whether an enhanced dopamine (da) inhibition on pituitary thyrotrophs and gonadotrophs may account for the abnormal tsh and lh dynamics in pathological hyperprolactinemia, we examined the effect of an acute lysis of the putative da overinhibition, as obtained with continuous domperidone (dom) infusion, on both basal and trh-gnrh stimulated prl, tsh and lh release in both normal cycling women and patients with pathological hyperprolactinemia. |
1988-07-06 |
2023-08-11 |
Not clear |
| B Scoccia, A B Schneider, E L Marut, A Scommegn. Pathological hyperprolactinemia suppresses hot flashes in menopausal women. The Journal of clinical endocrinology and metabolism. vol 66. issue 4. 1988-04-19. PMID:3346363. |
the purpose of this report is to describe the effect of hyperprolactinemia on gonadotropin secretion and hot flashes in menopausal women before and after treatment with a dopamine agonist. |
1988-04-19 |
2023-08-11 |
Not clear |
| E P Pioro, B W Scheithauer, E R Laws, R V Randall, K T Kovacs, E Horvat. Combined thyrotroph and lactotroph cell hyperplasia simulating prolactin-secreting pituitary adenoma in long-standing primary hypothyroidism. Surgical neurology. vol 29. issue 3. 1988-04-07. PMID:3344469. |
lactotroph hyperplasia may result from excess trh, which stimulates lactotrophs with resultant hyperprolactinemia, or from reduced hypothalamic dopamine, thereby facilitating prolactin secretion. |
1988-04-07 |
2023-08-11 |
Not clear |
| J A Ramos, J R Pais, M Cebeira, J Fernandez-Rui. Role of estrogens on striatal dopaminergic activity. Journal of steroid biochemistry. vol 27. issue 4-6. 1988-02-25. PMID:2961941. |
results of activity of d-2 dopamine receptors showing that hyperprolactinemia fails to increase the number of these receptors do not support the hypothesis that circulating prolactin regulates the activity of these striatal dopamine receptors. |
1988-02-25 |
2023-08-11 |
rat |
| R A Prysor-Jones, J J Silverlight, J S Jenkin. Hyperprolactinemia reduces vasoactive intestinal peptide in the anterior pituitary glands of rats. Neuroscience letters. vol 80. issue 3. 1988-01-20. PMID:3683988. |
the concentration of vasoactive intestinal polypeptide (vip) in the anterior pituitary gland of female rats was significantly reduced by pituitary implants, prolactin-secreting tumours or dopamine blockade-induced hyperprolactinemia. |
1988-01-20 |
2023-08-11 |
rat |
| b' G M Prelevi\\xc4\\x87, M I W\\xc3\\xbcrzburger, L A Peri\\xc4\\x8. Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome. Journal of endocrinological investigation. vol 10. issue 4. 1988-01-06. PMID:3119696.' |
these results suggest that a reduction of an inhibitory influence of hypothalamic dopamine might be a cause of inappropriately elevated lh and prl levels found in patients with polycystic ovary syndrome and hyperprolactinemia. |
1988-01-06 |
2023-08-11 |
Not clear |
| S R Fox, M T Hoefer, A Bartke, M S Smit. Suppression of pulsatile LH secretion, pituitary GnRH receptor content and pituitary responsiveness to GnRH by hyperprolactinemia in the male rat. Neuroendocrinology. vol 46. issue 4. 1987-12-02. PMID:2823160. |
control animals were untreated or were chronically hyperprolactinemic rats in which the hyperprolactinemia was transiently reversed by treatment for 3 days with the dopamine agonist 2-alpha-bromoergocryptine. |
1987-12-02 |
2023-08-11 |
rat |
| F V Shikaeva, G P Korenev. [Functional interrelations of monoamines, thyrotropic hormone and thyroid hormones in hyperprolactinemia]. Problemy endokrinologii. vol 33. issue 4. 1987-11-10. PMID:2889207. |
functional interrelationships of serotonin, dopamine, prolactin, trh and thyroid hormones in patients with hyperprolactinemia were studied. |
1987-11-10 |
2023-08-11 |
Not clear |
| J L Voogt, W J de Greef, T J Visser, J de Koning, J T Vreeburg, R F Webe. In vivo release of dopamine, luteinizing hormone-releasing hormone and thyrotropin-releasing hormone in male rats bearing a prolactin-secreting tumor. Neuroendocrinology. vol 46. issue 2. 1987-10-07. PMID:3114662. |
since the use of urethane anesthesia may change quantitatively and qualitatively the effects of hyperprolactinemia, it was decided to study these effects on the in vivo release of lhrh, dopamine and trh in conscious rats by a push-pull perfusion of the median eminence-arcuate nucleus area. |
1987-10-07 |
2023-08-11 |
rat |
| G B Melis, M Gambacciani, A M Paoletti, F Beneventi, V Mais, P Baroldi, P Fiorett. Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women. The Journal of clinical endocrinology and metabolism. vol 65. issue 3. 1987-09-25. PMID:3624413. |
two different single doses (400 and 600 micrograms) of the new long-acting dopamine agonist cabergoline (cbg) were given to 12 normal cycling women, 17 puerperal women, and 24 hyperprolactinemic women (12 with idiopathic hyperprolactinemia and 12 with pituitary adenoma). |
1987-09-25 |
2023-08-11 |
Not clear |
| D G Morgan, J S Randall, N A Telford, M N Gordon, Y N Sinha, C E Finch, P K Randal. Genotypic influences on pituitary responsiveness to haloperidol in mice. Psychoneuroendocrinology. vol 12. issue 3. 1987-08-31. PMID:3615750. |
others have speculated that the peripheral hyperprolactinemia produced by haloperidol is necessary for the striatal dopamine receptor supersensitization produced by dopamine antagonists. |
1987-08-31 |
2023-08-11 |
mouse |
| I Nicoletti, F Ambrosi, M C Pagliacci, G Pelicci, C Giammartino, D Maggio, L Fedeli, P Filippon. Catecholamines and pituitary function. VI. Effect of different dopamine doses on TRH-induced prolactin release in women with pathological hyperprolactinemia. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 19. issue 3. 1987-06-05. PMID:3106177. |
effect of different dopamine doses on trh-induced prolactin release in women with pathological hyperprolactinemia. |
1987-06-05 |
2023-08-11 |
Not clear |
| H Stracke, W Heinlein, R Horowski, H Schat. Dopamine agonists in the treatment of hyperprolactinemia. Comparison between bromocriptine and lisuride. Arzneimittel-Forschung. vol 36. issue 12. 1987-04-29. PMID:3566845. |
dopamine agonists in the treatment of hyperprolactinemia. |
1987-04-29 |
2023-08-11 |
Not clear |
| H Stracke, W Heinlein, R Horowski, H Schat. Dopamine agonists in the treatment of hyperprolactinemia. Comparison between bromocriptine and lisuride. Arzneimittel-Forschung. vol 36. issue 12. 1987-04-29. PMID:3566845. |
27 patients (12 women and 15 men) with hyperprolactinemia were treated with the dopamine agonists lisuride (dopergin) and bromocriptine on a cross-over basis for 3-6 months. |
1987-04-29 |
2023-08-11 |
Not clear |
| J M Rabey, E Graff, Z Oberman, S Flechter, J Vard. Selective regional effect of various neuroactive drugs on bromocriptine concentration in the brain of rats. Acta neurologica Scandinavica. vol 74. issue 4. 1987-03-18. PMID:3811835. |
bromocriptine (2-br-alpha-ergocryptine), a partial ergoline derivative, is a dopamine agonist which has been used successfully in the treatment of hyperprolactinemia, acromegaly and parkinson's disease. |
1987-03-18 |
2023-08-11 |
rat |
| R D Jackson, W B Malarke. Sequential prolactin evaluation of a "cured" patient with recurrence of prolactinoma. The American journal of medicine. vol 82. issue 2. 1987-03-17. PMID:3812533. |
several investigators have suggested that prolactin secretion in some subjects with hyperprolactinemia associated with pituitary macroadenomas may have a resistance to the prolactin inhibitory hormone, dopamine. |
1987-03-17 |
2023-08-11 |
human |